Two patients without cirrhosis discontinued treatment due to adverse events. Within the primary efficacy patient population, there have been no on-treatment virologic failures and 2.8 % of patients experienced relapse. AbbVie will disclose detailed GIFT-I study results at potential scientific congresses and in publications.. AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection AbbVie released top-line Phase 3 outcomes for its investigational, all-oral, ribavirin -free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir in sufferers with genotype 1b chronic hepatitis C virus infection in Japan.Eye deviation created; CT scanning showed the right frontal infarct, a deep thalamic hemorrhage, and large subdural collections which were consistent with abscess formation and hemorrhage. Four weeks later, blood cultures were positive for E. Coli, klebsiella, and serratia. The bacteremia resolved after surgical drainage of the subdural abscess. At 8 months old, she received an unrelated-donor cord-bloodstream transplant after myeloablative conditioning. She had slow T-cell engraftment. Four months after transplantation, she had mixed chimerism with 85 percent donor CD3+ cells. She has remained clinically well except for neurologic sequelae. Genetic and Other Analyses The techniques for immunologic phenotyping, genetic and protein analyses, and functional investigations are described at length in the Supplementary Appendix.